Top Page
Profound Medical
(TSX:PRN)
Profound Medical (PRN) vs. iShares MSCI Canada ETF (EWC)
Profound Medical Business Overview & Revenue Model
Profound Medical Earnings Call Summary
Profound Medical Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 22.49M | 10.68M | 7.20M | 6.68M | 6.87M |
| Gross Profit | 15.92M | 7.04M | 4.38M | 3.02M | 2.95M |
| EBITDA | -56.86M | -32.13M | -27.00M | -34.63M | -28.65M |
| Net Income | -59.48M | -27.82M | -28.57M | -28.67M | -30.70M |
Balance Sheet | |||||
| Total Assets | 193.10M | 70.23M | 43.91M | 64.42M | 86.78M |
| Cash, Cash Equivalents and Short-Term Investments | 81.87M | 54.91M | 26.21M | 46.52M | 67.15M |
| Total Debt | 6.46M | 5.12M | 7.87M | 8.23M | 1.38M |
| Total Liabilities | 102.04M | 9.81M | 12.73M | 12.42M | 6.16M |
| Stockholders Equity | 91.06M | 60.42M | 31.18M | 52.00M | 80.62M |
Cash Flow | |||||
| Free Cash Flow | -53.63M | -23.45M | -22.30M | -25.80M | -22.95M |
| Operating Cash Flow | -53.39M | -23.45M | -22.30M | -25.80M | -22.36M |
| Investing Cash Flow | -338.14K | 0.00 | 0.00 | 0.00 | -593.00K |
| Financing Cash Flow | 57.48M | 54.70M | 1.46M | 7.03M | 5.95M |
Profound Medical Technical Analysis
Profound Medical Risk Analysis
Profound Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | C$221.44M | -36.01 | -9.93% | ― | 2.48% | -53.76% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$21.58M | -5.28 | 106.68% | ― | 28.59% | 23.46% | |
46 Neutral | C$253.69M | -5.47 | -85.73% | ― | 72.03% | -1.47% | |
46 Neutral | C$21.47M | -29.60 | -31.12% | ― | 9.71% | -118.02% | |
46 Neutral | C$75.83M | -11.76 | -269.41% | ― | 1.46% | 6.91% | |
42 Neutral | C$58.64M | -1.50 | -181.70% | ― | 209.29% | 35.38% |
Profound Medical Corporate Events
Profound Medical will unveil the first clinical outcomes from its Level 1 post-market CAPTAIN trial, which compares the safety and efficacy of the TULSA Procedure with robotic radical prostatectomy in localized prostate cancer, at the European Association of Urology 2026 Congress in London on March 13. The data will be presented by leading urologist Dr. Laurence Klotz, after which the company will issue a summary release and host an investor webinar to review the clinical findings and discuss the commercial implications and steps toward potential inclusion of TULSA in prostate cancer treatment guidelines.
In addition, Profound’s management will hold a series of one-on-one investor meetings at the 38th Annual Roth Conference in Dana Point, California, from March 22 to 24, underscoring the company’s efforts to deepen engagement with the investment community. Together, these events highlight Profound’s push to validate TULSA clinically against surgical standards and to leverage emerging data to strengthen its positioning in the prostate cancer treatment market and broaden investor awareness.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$7.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical reported record fourth-quarter 2025 revenue of $6.0 million, up 43% year over year, driven by growing adoption of its TULSA-PRO system, which now has an installed base of 78 sites and a qualified pipeline of 110 additional systems, with management expecting about 120 installs by the end of 2026. The company highlighted broad real-world use of TULSA-PRO across prostate cancer and benign prostatic hyperplasia cases, new clinical data from leading centers, and the launch of its TULSA-AI Volume Reduction module, which it believes could triple its addressable prostate disease market to roughly 600,000 patients annually.
Profound also advanced its global commercial strategy by regaining exclusive TULSA-PRO distribution rights in Canada and signing distribution agreements in Saudi Arabia, Australia, and New Zealand, while a milestone at the Hong Center Scottsdale underscored growing urologist-led adoption. In December 2025, the company strengthened its balance sheet with more than $42 million in new equity financing from healthcare-focused and existing investors, supporting its commercial expansion and positioning it to compete more aggressively in the prostate therapy market.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$10.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical has announced its participation in two upcoming investor conferences in February, where management will hold a series of one-on-one meetings with institutional investors at the Lake Street Life-Sciences Invitational in Scottsdale, Arizona, and the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. While no webcasts will be available due to the meeting formats, the events underscore the company’s ongoing efforts to deepen engagement with the investment community and highlight the commercial progress and broader therapeutic potential of its TULSA-PRO and Sonalleve platforms across prostate and women’s health markets.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical reported that it exceeded its 2025 goal for TULSA-PRO installations, ending the year with 78 systems deployed versus a target of 75, and disclosed a qualified sales pipeline of 97 additional systems in advanced stages of the sales process. Management highlighted that the expanding installed base is expected to drive higher patient treatment volumes and growth in high-margin recurring revenue, reinforcing the TULSA Procedure’s positioning as a versatile, incision-free option across the prostate disease spectrum and underscoring Profound’s strengthening commercial traction ahead of its upcoming fourth-quarter and full-year 2025 financial results.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$12.50 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical announced that The Johns Hopkins Hospital has performed its first commercial, non-trial prostate cancer treatment using the company’s TULSA-PRO system, coinciding with the launch of Johns Hopkins Medicine’s new interventional MRI suite designed to turn MRI from a purely diagnostic tool into a real-time therapeutic platform. The milestone places TULSA-PRO within one of the world’s most influential prostate cancer centers, potentially accelerating adoption of the incision-free TULSA Procedure as a mainstream option for prostate cancer and enlarged prostate, and underscores a broader shift toward MRI-guided, minimally invasive therapies that promise faster recovery and fewer side effects compared with traditional surgery or radiation, with positive implications for Profound Medical’s market positioning in advanced prostate care.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. has closed a private placement of 921,428 common shares to Canadian investors at US$7.00 per share, raising approximately US$6.45 million in gross proceeds, with the shares subject to a four-month-plus-one-day hold period under Canadian securities laws. The company plans to deploy the funds to expand sales and marketing, support working capital, and advance research and development and potential strategic transactions, a move that strengthens its balance sheet and provides additional capital to drive commercialization of its MRI-guided therapeutic platforms and broader corporate growth initiatives.
The most recent analyst rating on (TSE:PRN) stock is a Hold with a C$10.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. has upsized its previously announced private placement to raise up to US$6.45 million through the issuance of as many as 921,428 common shares at US$7.00 per share, in order to accommodate demand from a long-term existing investor. The financing, expected to close by December 30, 2025 and subject to a standard four-month-plus-one-day hold period, will provide additional capital to expand sales and marketing, fund working capital and R&D, support potential strategic transactions and general corporate purposes, strengthening the company’s balance sheet as it seeks to scale commercialization of its MRI-guided, incision-free therapeutic platforms in competitive global medtech markets.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. has raised approximately $36 million through a registered direct offering of 5,142,870 common shares priced at $7.00 each, in a deal led by healthcare-focused investors and existing shareholders, with no warrant coverage. The company plans to deploy the net proceeds to expand sales and marketing, bolster working capital, fund research and development, pursue strategic transactions, and support general corporate purposes, and it also intends to complete an additional private placement for certain Canadian investors by December 30, 2025, subject to regulatory approvals, further strengthening its balance sheet and growth capacity.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.
Profound Medical Corp. has priced a financing of up to $40 million, consisting of a $36 million registered direct offering of 5,142,857 common shares at $7.00 each and a planned $4 million private placement in Canada of up to 571,428 common shares at the same price. The registered direct offering, which carries no warrant coverage and is led by healthcare-dedicated investors alongside existing shareholders, is expected to close around December 22, 2025, while the Canadian private placement, subject to stock exchange and other approvals and a four-month-plus-one-day hold period, is expected to close by December 30, 2025. Profound plans to deploy the net proceeds to expand sales and marketing, bolster working capital, fund research and development, pursue strategic transactions, and support general corporate purposes, reinforcing its capital position as it works to scale commercialization of its prostate disease treatment platform. Konik Capital Partners, a division of T.R. Winston and Company, is acting as exclusive placement agent for the registered direct component.
The most recent analyst rating on (TSE:PRN) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Profound Medical stock, see the TSE:PRN Stock Forecast page.